You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
微創機器人-B(02252.HK):Mona Lisa前列腺穿刺機器人完成多中心註冊臨牀試驗入組

格隆匯5月2日丨微創機器人-B(02252.HK)宣佈,公司與Biobot Surgical Pte. Ltd.聯合在華成立的合資公司上海介航機器人有限公司("微創介航機器人")所屬產品Mona Lisa前列腺穿刺機器人定位系統("Mona Lisa")完成了全部註冊臨牀試驗入組。此次註冊臨牀試驗由南京大學醫學院附屬鼓樓醫院作為組長單位,聯合西安交通大學第一附屬醫院和蘇北人民醫院共同參研。Mona Lisa在手術過程中運行穩定,操作安全,流程順暢,在手術安全性、學習曲線和穿刺檢出率等方面較傳統手術人工穿刺方式具有明顯優勢,臨牀價值較大。

Mona Lisa是公司在經皮穿刺這一賽道佈局的一款創新機器人產品,旨在輔助醫生更加安全、精確、智慧、高效地完成前列腺穿刺活檢手術。依託手術機器人與人工智慧技術,Mona Lisa可通過智慧軟件制定方案,輔助臨牀醫生更好地完成各項操作,不僅展示了3D可視化MRI-超聲融合技術,且其運動補償和針偏移位置補償技術進一步提高了穿刺手術的精準性,減少漏診率,減少創口數量,減輕患者痛苦。

隨着本次臨牀入組的完成,Mona Lisa成為了國內首款在泌尿外科領域完成註冊臨牀試驗入組的前列腺穿刺機器人,同時也是公司在經皮穿刺領域新的突破,標誌着集團向前列腺癌的精準診治邁出的關鍵一步。微創介航機器人計劃於2022年第三季度向國家藥品監督管理局遞交Mona Lisa的註冊申請。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account